RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CRISPR Therapeutics Stock

CRISPR Therapeutics ROE 2025

CRISPR Therapeutics ROE

-0.08

Ticker

CRSP

ISIN

CH0334081137

WKN

A2AT0Z

In 2025, CRISPR Therapeutics's return on equity (ROE) was -0.08, a -76.47% increase from the -0.35 ROE in the previous year.

CRISPR Therapeutics Aktienanalyse

What does CRISPR Therapeutics do?

CRISPR Therapeutics AG is a company specializing in the development of therapies based on the gene editing technology CRISPR-Cas9. The company was founded in 2013 in Basel, Switzerland and is now headquartered in Zug, Switzerland. CRISPR Therapeutics is listed on the NASDAQ stock exchange and also has offices in the USA and London. CRISPR Therapeutics AG's history is closely linked to the discovery and development of the CRISPR-Cas9 technology. This revolutionary technique allows for the targeted modification, repair or elimination of certain genes in the genome of organisms. The technology was first discovered in the 1990s, but it was only in recent years with the development of CRISPR-Cas9 that it became possible to apply this technique in medical research. The goal of CRISPR Therapeutics AG is to use the CRISPR-Cas9 technology to develop therapies for life-threatening genetic diseases. The company works closely with the academic community and industry to develop innovative therapies and bring them through clinical trials. The business model of CRISPR Therapeutics AG is based on the development and commercialization of therapies based on the CRISPR-Cas9 technology. This involves using the technology to treat the genetic causes of serious diseases such as cystic fibrosis, sickle cell anemia, beta-thalassemia, or certain types of cancer. The company has a number of products in its pipeline and works closely with partners such as Vertex Pharmaceuticals and Bayer. CRISPR Therapeutics operates in the biotechnology industry and is divided into various divisions. For example, there is the research and development (R&D) division, which focuses on developing new therapies based on the CRISPR-Cas9 technology. Here, the company works on its own research projects as well as joint research projects with partners. There is also a clinical studies department that aims to test new therapies, prove their efficacy and safety in humans, and produce approved therapeutics. An example of a current product from the company is the CTX001 therapy, which involves stem cell transplantation using genetically modified stem cells from healthy donors to produce genetically error-free blood cells in the patient's body. CTX001 is currently in phase 1/2a clinical trials for the treatment of beta-thalassemia and sickle cell anemia, and is being jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals. In summary, CRISPR Therapeutics AG is a company in the biotechnology industry specializing in the development and commercialization of therapies based on the CRISPR-Cas9 technology. The company has a number of products in its pipeline and works closely with partners to develop innovative therapies and bring them through clinical trials. With the CRISPR-Cas9 technology, there is the potential to combat genetic diseases, which could have a significant impact on the treatment of diseases in the future. CRISPR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding CRISPR Therapeutics's Return on Equity (ROE)

CRISPR Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing CRISPR Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

CRISPR Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in CRISPR Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about CRISPR Therapeutics stock

What is the ROE (Return on Equity) of CRISPR Therapeutics this year?

The ROE of CRISPR Therapeutics this year is -0.08 undefined.

How has the Return on Equity (ROE) of CRISPR Therapeutics developed compared to the previous year?

The ROE of CRISPR Therapeutics has increased by -76.47% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of CRISPR Therapeutics?

A high ROE indicates that CRISPR Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of CRISPR Therapeutics?

A low ROE can indicate that CRISPR Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of CRISPR Therapeutics affect the company?

A change in ROE (Return on Equity) of CRISPR Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of CRISPR Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of CRISPR Therapeutics?

Some factors that can influence CRISPR Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does CRISPR Therapeutics pay?

Over the past 12 months, CRISPR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CRISPR Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CRISPR Therapeutics?

The current dividend yield of CRISPR Therapeutics is .

When does CRISPR Therapeutics pay dividends?

CRISPR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CRISPR Therapeutics?

CRISPR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CRISPR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CRISPR Therapeutics located?

CRISPR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CRISPR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CRISPR Therapeutics from 1/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/18/2025.

When did CRISPR Therapeutics pay the last dividend?

The last dividend was paid out on 1/18/2025.

What was the dividend of CRISPR Therapeutics in the year 2024?

In the year 2024, CRISPR Therapeutics distributed 0 USD as dividends.

In which currency does CRISPR Therapeutics pay out the dividend?

The dividends of CRISPR Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CRISPR Therapeutics

Our stock analysis for CRISPR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CRISPR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.